The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk's weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...

On Tuesday, French AI startup Mistral AI released Devstral 2, a 123 billion parameter open-weights coding model designed to work as part of an autonomous software engineering agent. The model achieves ...

Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...

Andy Richter is getting candid about his looks. After sharing he's lost weight during season 34 of Dancing With the Stars, the comedian reflected on the public fascination with his body size ...

View post: Amazon Is Selling a $28 Smart Floor Lamp, and It Curates the Coolest Vibes Dwayne “The Rock” Johnson is stunning fans with a major transformation. A viral TikTok and X video shows “The Rock ...

Williams used GLP-1 drugs to lose weight after childbirth Williams' sign-on adds credibility to the company's offering, investor says Williams' husband Alexis Ohanian is Ro investor, serves on board ...

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.

OpenAI just dropped two new open-weights models. Here's why that isn't the same as being fully open. Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video ...

We may earn a commission from links on this page. Credit: Image courtesy of Nike. If you're building out a home gym, the first piece of equipment you need is a set of weights. While I'm a huge fan of ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.